GlassScriptPhysician profile
Behrad Ben Aynehchi
NPI 1275709040
$3,049.78
in general payments reported to CMS, 2019-2025
19 companies · $985 in 2025
The $985 reported for 2025 was more than what 81% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $49.95 · 2021: $284 · 2022: $593 · 2023: $546 · 2024: $287 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $695.34 | 2022-2025 | Dupixent |
| Stryker Corporation | $694.38 | 2019-2025 | Xpress Loprofile, Xpress Ent Dilation System, Cyclone Sinonasal Suction/Irrigation System |
| Glaxosmithkline, LLC. | $461.63 | 2021-2025 | Nucala |
| Abbvie INC. | $232.85 | 2023-2025 | Botox |
| Acclarent, INC | $178.20 | 2019-2023 | Trudi Nav Cable |
| Genzyme Corporation | $173.09 | 2024-2025 | |
| Optinose US, INC. | $168.52 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $91.65 | 2022-2025 | Ryaltris |
| Neurent Medical Limited | $66.69 | 2022-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Aerin Medical INC. | $57.80 | 2022-2023 | |
| Intersect Ent, INC. | $56.34 | 2019 | |
| Phathom Pharmaceuticals, INC. | $29.72 | 2025 | Voquezna |
| Medtronic, INC. | $27.95 | 2023 | Propel |
| Merck Sharp & Dohme LLC | $26.40 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.95 | 2025 | Tezspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $19.45 | 2019 | |
| Organogenesis INC. | $18.84 | 2023 | Puraply |
| Kaleo, INC. | $17.74 | 2021 | |
| Smith+Nephew, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behrad Aynehchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.